Biomarker development in the precision medicine era: lung cancer as a case study

被引：408
作者：
Vargas, Ashley J. [1 ,2 ]
Harris, Curtis C. [1 ]
机构：
[1] NCI, Lab Human Carcinogenesis, Ctr Canc Res, Room 3068A,MSC 425,837 Convent Dr, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Rockville, MD 20850 USA
来源：
NATURE REVIEWS CANCER | 2016年 / 16卷 / 08期
关键词：
C-REACTIVE PROTEIN; REPORTING RECOMMENDATIONS; GENE-EXPRESSION; INTERNATIONAL-ASSOCIATION; PROGNOSTIC CLASSIFIER; COMPANION DIAGNOSTICS; AFRICAN-AMERICANS; EGFR MUTATIONS; MESSENGER-RNA; NEVER SMOKERS;
D O I：
10.1038/nrc.2016.56
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision medicine relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. Although affordable 'omics'-based technology has enabled faster identification of putative biomarkers, the validation of biomarkers is still stymied by low statistical power and poor reproducibility of results. This Review summarizes the successes and challenges of using different types of molecule as biomarkers, using lung cancer as a key illustrative example. Efforts at the national level of several countries to tie molecular measurement of samples to patient data via electronic medical records are the future of precision medicine research.
引用
收藏
页码：525 / 537
页数：13
相关论文
共 170 条
  • [1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [2] Ahmad A., 2016, Lung Cancer and Personalized Medicine: Current Knowledge and Therapies
  • [3] Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma
    Akagi, Ichiro
    Okayama, Hirokazu
    Schetter, Aaron J.
    Robles, Ana I.
    Kohno, Takashi
    Bowman, Elise D.
    Kazandjian, Dickran
    Welsh, Judith A.
    Oue, Naohide
    Saito, Motonobu
    Miyashita, Masao
    Uchida, Eiji
    Takizawa, Toshihiro
    Takenoshita, Seiichi
    Skaug, Vidar
    Mollerup, Steen
    Haugen, Aage
    Yokota, Jun
    Harris, Curtis C.
    [J]. CANCER RESEARCH, 2013, 73 (13) : 3821 - 3832
  • [4] Epidemiology of lung cancer
    Alberg, AJ
    Samet, JM
    [J]. CHEST, 2003, 123 (01) : 21S - 49S
  • [5] Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer
    Alifano, Marco
    Falcoz, Pierre E.
    Seegers, Valerie
    Roche, Nicolas
    Schussler, Olivier
    Younes, Mohamad
    Antonacci, Filippo
    Forgez, Patricia
    Dechartres, Agnes
    Massard, Gilbert
    Damotte, Diane
    Regnard, Jean-Francois
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 142 (05) : 1161 - 1167
  • [6] Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
    Altman, Douglas G.
    McShane, Lisa M.
    Sauerbrei, Willi
    Taube, Sheila E.
    [J]. PLOS MEDICINE, 2012, 9 (05)
  • [7] Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
    Altman, Douglas G.
    McShane, Lisa M.
    Sauerbrei, Willi
    Taube, Sheila E.
    [J]. PLOS MEDICINE, 2012, 9 (05)
  • [8] Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
  • [9] [Anonymous], DEF GEN BIOM PHARM P
  • [10] [Anonymous], FDA APPR KEYTR ADV N
12345678910